TiGenix NV's CEO feels sure the pipeline-stage company's lead asset - a cell-based treatment for complex perianal fistula - can get a go-ahead recommendation next month for Europe, and is already finalizing commercialization plans with Takeda Pharmaceutical Co. Ltd., its partner for the drug in the region.
Eduardo Bravo told Scrip that he is "confident" TiGenix has provided evaluators at the European Medicines Agency what is needed...






